Clinical Significance of Different Profiles of anti-Ro Antibodies in Connective Tissue Diseases

Table 3

Comparison of clinical features in patients with connective tissue diseases.

Parameters (, %)	Groups				values			Overall
	All:	Group A: Ro52 alone	Group B: Ro60 alone	Group C: Ro60 and Ro52	Group A vs. group B	Group A vs. group C	Group B vs. group C
Disease duration, years ()					0.019	<0.0001	0.063	<0.0001
Skin rash	349 (26.5)	40 (23.7)	101 (35.7)	208 (24.0)	0.008	0.928	<0.0001	<0.0001
Alopecia	99 (7.5)	6 (3.6)	37 (13.1)	56 (6.5)	0.001	0.145	<0.0001	<0.0001
Oral ulcer	55 (4.2)	6 (3.6)	16 (5.7)	33 (3.8)	0.315	0.873	0.182	0.366
Arthralgia	512 (38.8)	72 (42.6)	164 (58.0)	276 (31.8)	0.002	0.007	<0.0001	<0.0001
Myalgia	80 (6.1)	16 (9.5)	26 (9.2)	38 (4.4)	0.921	0.007	0.002	0.002
Xerophthalmia	277 (21.0)	31 (18.3)	39 (13.8)	207 (23.9)	0.160	0.118	<0.0001	0.001
Xerostomia	310 (23.5)	34 (20.1)	47 (16.6)	229 (26.4)	0.346	0.085	0.001	0.002
Anemia	375 (28.4)	39 (23.1)	78 (27.6)	258 (29.8)	0.292	0.079	0.481	0.198
Leukocytopenia	295 (22.4)	28 (16.6)	61 (21.6)	20 6(23.8)	0.197	0.041	0.446	0.114
Thrombocytopenia	128 (9.7)	11 (6.5)	27 (9.5)	90 (10.4)	0.261	0.121	0.685	0.297
Proteinuria	208 (15.8)	10 (5.9)	53 (18.7)	145 (16.7)	<0.0001	<0.0001	0.438	0.001
Hematuria	99 (7.5)	3 (1.8)	29 (10.2)	67 (7.7)	0.001	0.005	0.183	0.004
ILD	211 (16.0)	60 (35.5)	32 (11.3)	119 (13.7)	<0.0001	<0.0001	0.296	<0.0001
PAH	63 (4.8)	17 (10.1)	15 (5.3)	31 (3.6)	0.056	<0.0001	0.199	0.001
RP	88 (6.7)	18 (10.7)	22 (7.8)	48 (5.5)	0.297	0.013	0.172	0.036

ILD: interstitial lung disease; PAH: pulmonary arterial hypertension; RP: Raynaud’s phenomenon.